Iatrogenic Menopause.pdf (132.85 kB)
Iatrogenic menopause after treatment for cervical cancer
journal contributionposted on 2016-12-15, 09:12 authored by E.L. Moss, S. Taneja, Fehmidah MunirFehmidah Munir, C. Kent, L. Robinson, N. Potdar, P. Sarhanis, Hilary McDermottHilary McDermott
The ever-improving prognosis of women diagnosed with cervical cancer has meant that survivorship and treatment-related sequelae are being brought more into the spotlight in an attempt to try to reduce morbidity and improve women's long-term health. However, there are many issues surrounding an iatrogenic menopause in cervical cancer, a variety of potential management options and barriers to treatment. Women who have become menopausal under the age of 45 years as a result of cervical cancer are significantly less likely to start hormone replacement therapy (HRT) or continue it long term as compared with those who have undergone a surgical menopause for a benign reason. High profile media reports raising concerns about the safety of HRT use have left many women reluctant to consider HRT as a therapeutic option for menopausal symptoms and many are seeking to use complementary/alternative medicine, including non-pharmacological interventions, to alleviate symptoms. The benefits of HRT in this population have been shown to reduce these effects, although adherence to treatment regimens is a challenge due to poor compliance, which is in part due to the fear of a second malignancy. The development of non-HRT-based interventions to ameliorate menopausal symptoms and reduce the long-term health consequences are needed for women who choose not to take HRT.
- Sport, Exercise and Health Sciences
Published inClinical Oncology
Pages766 - 775
CitationMOSS, E.L. ... et al., 2016. Iatrogenic menopause after treatment for cervical cancer. Clinical Oncology, 28 (12), pp. 766 - 775.
Publisher© Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
- AM (Accepted Manuscript)
Publisher statementThis work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/
NotesThis article was published in the journal Clinical Oncology [© Published by Elsevier Ltd on behalf of The Royal College of Radiologists] and the definitive version is available at: http://dx.doi.org/10.1016/j.clon.2016.08.016